Effect of TYB-2285 on lung anaphylaxis in actively sensitized rats.

Akihiko Watanabe, Takanari Tominaga, Haruyuki Shutoh, Haruki Hayashi, Jun-ichi Tsuji, Akihide Koda, Hiroichi Nagai*, Yoshio Kumazawa, Hideyo Shimada

We examined the effect of TYB-2285 on the acute phase and the late phase of lung anaphylaxis in rats. TYB-2285 (3-30 mg/kg) inhibited antigen-induced bronchoconstriction and thromboxane B2 production during the acute phase of lung anaphylaxis more potently than ketotifen fumarate (30 mg/kg). TYB-2285 also inhibited the accumulation of neutrophils but not total cells during the late phase of lung anaphylaxis. Hydrocortisone acetate (100 mg/kg p.o.) inhibited the accumulation of total cells as potent as neutrophils.

Effect of TYB-2285 on passive cutaneous anaphylaxis in rats.

Akihiko Watanabe, Takanari Tominaga, Haruyuki Shutoh, Haruki Hayashi, Jun-ichi Tsuji, Akihide Koda, Hiroichi Nagai*, Yoshio Kumazawa, Hideyo Shimada

TYB-2285 (1-30 mg/kg, p.o.) inhibited ovalbumin- and dinitrophenyl-ascaris-induced passive cutaneous anaphylaxis (PCA) in a dose-dependent manner. Moreover, TYB-2285 (3-30 mg/kg, p.o.) inhibited histamine consumption at the PCA site. Unlike cyproheptadine or amlexanox, TYB-2285 (30 mg/kg, p.o.) did not inhibit histamine-, serotonin-, ascites-, compound 48/80-, or A23187-induced capillary permeability. These results demonstrate that TYB-2285 inhibites PCA by inhibiting histamine release, although it does not inhibit capillary permeability.

Immunomodulatory action of levofloxacin on cytokine production by human peripheral blood mononuclear cells

Tomoaki Yoshimura, Chikako Kurita, Eiseki Usami, Toshiya Nakao, Shino Watanabe, Joji Kobayashi, Futoshi Yamazaki, Hiroichi Nagai*

Levofloxacin (LVFX) increased interleukin-2 (IL-2) production by peripheral blood mononuclear cells (PBMC) stimulated with phytohemagglutinin (PHA) in a dose-dependent manner. LVFX suppressed granulocyte-macrophage colony-stimulating factor and soluble IL-2 receptor production. LVFX inhibited the production of IL-1 β and Tumor necrosis factor α by lipopolysaccharide-stimulated PBMC. These results show that LEVX has an immunomodulatory action on cytokines production by PBMC independent of its antimicrobial activity.